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Abstract
Background The therapeutic landscape for non-small-cell lung cancer (NSCLC) patients that have common epidermal growth 
factor receptor (EGFR) mutations has changed radically in the last decade. The availability of these treatment options has 
an economic impact, therefore a budget impact analysis was performed.
Methods A budget impact analysis was conducted from a Dutch healthcare perspective over a 5-year time horizon in 
EGFR-mutant NSCLC patients receiving first-line afatinib  (Gilotrif®) versus first-line osimertinib  (Tagrisso®), followed 
by subsequent treatments. A decision analysis model was constructed in Excel. Scenario analyses and one-way sensitivity 
analysis were used to test the models’ robustness.
Results Sequential treatment with afatinib versus first-line treatment with osimertinib showed mean total time on treatment 
(ToT) of 29.1 months versus 24.7 months, quality-adjusted life months (QALMs) of 20.2 versus 17.4 with mean cost of 
€108,166 per patient versus €143,251 per patient, respectively. The 5-year total budget impact was €110.4 million for the 
afatinib sequence versus €158.6 million for the osimertinib sequence, leading to total incremental cost savings of €48.15 
million.
Conclusions First-line afatinib treatment in patients with EGFR-mutant NSCLC had a lower financial impact on the Dutch 
healthcare budget with a higher mean ToT and QALM compared to osimertinib sequential treatment.
Keywords Budget impact · Afatinib · Osimertinib · Treatment sequencing · I15 · I18
JEL Classification I15 · I18
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Background
Lung cancer is the worldwide leading cause of cancer mor-
tality [1]. Non-small-cell lung cancer (NSCLC) is the most 
common type with 40% of the patients presenting with 
adenocarcinoma [2] Approximately 10–20% of Caucasian 
patients with non-resectable lung adenocarcinoma have 
somatic mutations of the epidermal growth factor receptor 
(EGFR) gene. The therapeutic landscape for patients with 
advanced EGFR mutation-positive NSCLC (exon 19 dele-
tion and L858R) has changed radically with EGFR tyros-
ine kinase inhibitors (TKIs) becoming the new first-line 
standard treatment instead of chemotherapy. Data from 
multiple phase III randomized clinical trials (RCTs) have 
shown that the first-generation EGFR TKIs, erlotinib or 
gefitinib, and the second-generation EGFR TKI afatinib 
improved progression-free survival (PFS) and quality of 
life (QoL) compared to standard platinum-based chemo-
therapy [3–9]. More recent trials suggested that second-
generation EGFR TKIs (afatinib and dacomitinib) may 
be more effective than first-generation agents [10, 11]. 
Recently, a third-generation TKI, osimertinib, has shown 
improved PFS compared to first-generation TKIs [12].
Eventually, patients treated with first-line EGFR TKIs 
develop resistance to treatment. The majority of patients 
(50–70%) progressing on first- and second- generation 
TKIs, develop secondary mutations such as the T790M 
point mutation. For patients with T790M-positive tumors, 
osimertinib is an approved second-line treatment based on 
improved PFS compared to standard of care observed in 
the AURA3 study [13]. ESMO guidelines recommended 
T790M mutation testing in all patients progressing on 
first-line TKI treatment [2]. For patients progressing on 
first-line therapy without T790M mutation, guidelines 
described complex and heterogeneous molecular mecha-
nisms of resistance, for example, MET or HER2 amplifica-
tion, BRAF or KRAS mutations, and small cell transfor-
mation. For these patients, the current standard treatment 
is platinum-based doublet chemotherapy (PDC). When 
patients progress on first-line osimertinib, the most fre-
quent resistance mechanisms are MET amplification (15%) 
and EGFR C797S mutation (7%) [14]. There are currently 
no targeted treatment options available after osimertinib 
and patients failing first-line osimertinib treatment will 
receive chemotherapy or best supportive care [15, 16].
There is increasing evidence suggesting that patients 
treated with first-line afatinib are well suited for subse-
quent treatment with osimertinib. In a retrospective pooled 
analysis of data from 34 patients with common sensitiz-
ing EGFR mutations treated in the LUX-Lung 3, 6 and 7 
studies, the median time on sequential treatment with osi-
mertinib after first-line afatinib was 31.5 months [17]; the 
majority of patients were treated with osimertinib in the 
third, or later, line setting. Furthermore, a global obser-
vational real-world study showed that the median time 
on treatment for sequential first-line afatinib followed by 
second-line osimertinib was 27.6 months [18].
Due to the high number of life years lost by early death, 
lung cancer has one of the highest burdens of disease in the 
Netherlands [19, 20]. The economic impact of a first-line 
treatment with afatinib followed by re-biopsy guided osimer-
tinib therapy versus treatment of first-line osimertinib fol-
lowed by subsequent chemotherapy has not been assessed in 
the Netherlands. In this study, the medical cost of treatment 
and the budget impact of these different treatment options 
for patients with common EGFR mutations were evaluated.
Materials and methods
Model design
A decision-analytic model was constructed in Microsoft 
Excel to assess the budget impact of different first-line treat-
ment approaches in advanced or metastatic NSCLC patients 
with common EGFR mutations. The model compared two 
treatment strategies (Fig. 1): first-line afatinib  (Gilotrif®) 
followed by second-line osimertinib  (Tagrisso®) (T790M 
positive on progression) or chemotherapy (T790M negative 
on progression) followed by third-line chemotherapy ver-
sus first-line treatment osimertinib followed by second-line 
chemotherapy. Patients are assumed to go into the health 
states best supportive care (BSC) or death after failing 
chemotherapy. The analysis was performed from the Dutch 
healthcare perspective. The model estimated outcomes and 
costs for each treatment approach over a 5-year period. This 
analysis was developed in accordance with the International 
Society for Pharmacoeconomics and Outcomes Research’s 
good practices for budget impact analysis [21].
This budget impact analysis represents a base case. One-
way deterministic sensitivity analysis and scenario analy-




The eligible population included individuals with metastatic 
NSCLC whose tumors have EGFR deletion 19 or L858R 
mutations initiating first-line treatment. According to the 
Dutch Cancer Registration, there were 9175 patients with 
NSCLC in 2017 [20]. Approximately 10–20% of Cauca-
sian patients with non-resectable lung adenocarcinoma 
have somatic mutations of the EGFR gene [2], leading to 
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approximately 294 new patients every year in the Nether-
lands. It was assumed that a monthly mean of 24.5 new 
patients entered the model. A time horizon of 5 years was 
applied, in line with the decision-making context in the 
Netherlands. As this study is a budget impact analysis with 
a time horizon of 5 years, discounting was not applied.
Generation of dataset
To investigate the effect of treatment sequencing on time on 
treatment, a survival model with reconstructed individual 
patient time-to-event data was fitted using digitized PFS 
curves with data from controlled clinical trials. For afatinib 
as first-line treatment, patient level data from the LUX-Lung 
3 clinical trial were used to fit the PFS curves [8]. In the 
LUX-Lung 3 trial, afatinib showed significant improvement 
with a median PFS of 11.1 months in comparison to 6.9 
months of cisplatin plus pemetrexed in untreated advanced 
NSCLC patients with EGFR mutations [8]. To fit the PFS 
curves for the first-line treatment with osimertinib, data from 
the FLAURA clinical trial with untreated EGFR-mutated 
advanced NSCLC patients were applied. The FLAURA 
trial demonstrated a significantly longer median PFS of 18.9 
months with osimertinib versus standard EGFR TKIs gefi-
tinib and erlotinib with a median PFS of 10.2 months [12].
Eventually the majority of patients will develop resist-
ance to first-line treatment, mostly by developing secondary 
mutations such as the T790M point mutation. Data from 
the AURA3 [13] and IMPRESS [22] studies was used for 
second-line osimertinib and chemotherapy, respectively. In 
the AURA3 trial, osimertinib showed a significant improve-
ment in median PFS at 10.1 months versus 4.4 months for 
chemotherapy (pemetrexed plus either carboplatin or cispl-
atin) in T790 mutation-positive advanced NSCLC patients. 
Furthermore in second-line treatment with chemotherapy, 
the IMPRESS trial showed that continuation of a standard 
EGFR TKI did not prolong PFS in patients who received 
PDC as a subsequent line of treatment [22]. Both treatment 
arms showed a median PFS of 5.4 months. For this reason, 
there will be no continuation of EGFR TKI treatment when 
chemotherapy is the second-line treatment. Because there 
is limited data on the efficacy of third-line chemotherapy, 
we assumed similar efficacy to second-line chemotherapy.
Fig. 1  Decision-analytic model to assess the budget impact of first-
line treatment with afatinib versus osimertinib in EGFR mutation-
positive NSCLC patients. BSC best supportive care, EGFR epidermal 
growth factor receptor, NSCLC non-small-cell lung cancer, PDC plat-
inum doublet chemotherapy
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The demographic characteristics of patients included 
in the RCTs of LUX-Lung 3, FLAURA, AURA3 and 
IMPRESS (published between 2015 and 2018) were well 
balanced [8, 12, 13, 22]. All patients included concerned 
adult patients with histological confirmed lung adenocarci-
noma, advanced or metastatic stage IIIB and IV with mainly 
the following common EGFR mutations: exon 19 deletion 
and exon 21 L858R point mutation (further mutation details 
are provided in Tables 4–7 in the Supplementary Data). The 
median age in the RCTs ranged from 60 to 64 years old and 
the distribution of female ranged 54–65%. The distribution 
of race ranged 32–36% for white, 62–79% for Asian and 
1–3% other. The studies LUX-Lung 3 and IMPRESS did 
not elaborate on the distribution between white and other, 
therefore a range of 21–28% concerns a combination of both 
for these studies. The WHO performance status 0 ranged 
from 40 to 41% and performance status 1 from 59 to 60%. 
A WHO performance status of 0 indicates that the patient 
is fully active and able to carry out all predisease activities 
without restrictions and a WHO performance status of 1 
indicates that the patient is restricted in physically strenuous 
activity but is ambulatory and able to carry out work of a 
light or sedentary nature, such as light office work [12]. Only 
the WHO performance status was not taken into account 
in the AURA3 study. The distribution of patient’s history 
of smoking was 65–67% for never, 30–32% for former and 
2–8% for current. In both the AURA3 and IMPRESS stud-
ies, it was unknown what the percentage of former and cur-
rent smokers was.
To ensure that survival data for patients with similar char-
acteristics were used in the model, the model and analyses 
were limited to patients with common mutations. A network 
meta-analysis (NMA) was performed, following a Bayesian 
framework with two designed and estimated networks. The 
description of the performed NMA is included in the Sup-
plementary Data. WebPlotDigitizer was used to extract the 
Kaplan–Meier data from the publications, R version 3.5.1 
and the SurvHE package was used to generate pseudo-
individual patient-level data [23]. The partitioned survival 
model with a Weibull distribution for the common mutations 
estimated the proportion of a cohort in each state. The mod-
eled PFS values were then used as proxy to estimate time on 
treatment for each intervention (Table 1).
Transition probabilities
Total time in progression-free disease and post-progression 
treatment options per treatment plan were calculated using 
a decision tree combining survival data and prescription 
data (Fig. 1). Mean survival time from survival modeling 
was used to calculate the expected time on treatment for 
the different interventions. In addition, data from real-
world studies were used in the model [24, 25]. Prevalence 
of detectable T790M rates depend on available diagnostic 
testing technology and have been reported to range from 
50 to 70% [17, 18, 26]. For patients treated with afatinib, a 
63% probability of a T790M mutation was used in the base 
case [25]. Estimates of the proportions of patients receiv-
ing subsequent therapy were taken from the literature. In 
the LUX-Lung trials, 71% of the intention-to-treat popu-
lation and 88% of patients from countries with universal 
reimbursement received subsequent treatment (Table 1) 
[17]. In FLAURA, 58% of patients progressing on first-line 
osimertinib received subsequent therapy and in AURA III 
41% of patients with T790M mutation-positive disease who 
progressed on second-line osimertinib received subsequent 
treatment [12, 13].
Due to limited availability of overall survival data for 
the modeled interventions, we have assumed that patients 
not receiving subsequent therapy following progression will 
continue to progress and receive best supportive care and/
or die.
Utilities
To be able to include adverse events into the budget impact 
model, disutilities related to specific adverse events in 
patients with NSCLC [27] were combined with data from 
health-related quality of life (HRQoL) in patients with 
NSCLC in different health states [28] (Table 1). The model 
considered ten grade ≥ 3 adverse events associated with 
treatment. Assumptions were made for dyspnea, leukope-
nia, paronychia, stomatitis based on available data [27]. For 
example, the utility of leukopenia was assumed to be the 
same as the utility of neutropenia. Table 1 gives an overview 
of all (dis)utilities, sources and assumptions.
Comparing the utility in progression-free (PF) patients on 
first-line treatment with PF patients on second-line treatment 
resulted in a slightly higher but not clinically relevant mean 
utility in patients on second-line treatment [28]. One poten-
tial explanation for this could be that patients who move 
on to a higher line of treatment comprise a subset that is 
relatively fit [28].
Costs
An overview of all healthcare costs used in the model is 
shown in Table 1. The base-case analysis was the Dutch 
healthcare perspective; only direct medical costs were con-
sidered. The costs of both afatinib and osimertinib are based 
on the price for a monthly prescription. The mean cost for 
having grade 3 adverse events was calculated per patient for 
every specific treatment step, irrespective of time on treat-
ment. In the model, every patient starting a specific treat-
ment step will have a mean cost for grade 3 adverse events 
irrespective of time on treatment. The cost of a T790M 
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Table 1  Overview of model parameters included in the budget impact model for sequential treatment with afatinib versus first-line osimertinib in 
NSCLC patients with common EGFR mutations
Mean Afatinib Osimertinib PDC BSC/death Source and assumptions
First-line Second-line
Transition probabilities—afatinib treatment arm
T790M mutation-positive
 First-line – 63% – – – – [25]
 Second-line – – 88% – – 12% Assumption
 Third-line – – – – 41% 59% [13]
 Fourth-line – – – – – 100% Assumption
T790M mutation-negative
 First-line – 37% – – – – [25]
 Second-line – – – – 88% 12% [10, 13]
 Third-line – – – – – 100% Assumption
Transition probabilities—osimertinib treatment arm
First-line – – 100% – – – –
Second-line – – – – 58% 42% [12]
Third-line – – – – – 100% Assumption
Disutilities and incidences of grade ≥ 3 adverse events
Anaemia  − 0.07346 0.44% 1.08% 0.72% 6.31% – [27]
Diarrhoea  − 0.0468 14.41% 2.15% 1.08% – –
Fatigue  − 0.07346 1.31% 0.72% 1.08% 12.61% –
Neutropenia  − 0.0897 0.44% – 1.43% 18.02% –
Rash  − 0.03248 16.16% 1.08% 0.72% – –
Dyspnea  − 0.07346 – 0.36% 1.08% – – Assumption based on 
disutilities from Nafees 
et al. [27]
Leukopenia  − 0.0897 0.44% – – 8.11% –
Paronychia  − 0.03248 11.35% 0.36% – – –
Stomatitis  − 0.0468 8.73% 0.36% – 0.90% –
Health states
First-line 0.710 0.688 0.707 0.672 – [8, 12, 13, 21, 26, 27] –
Second-line 0.730 0.708 0.727 0.692 – – –
Third-line 0.620 0.598 0.617 0.582 – – –
Simulated mean PFS from survival model
First-line – 16.99 20.80 – – [8, 12] –
Second-line – – 15.23 6.71 – [13] –
Third-line – – – 6.71 – [22] –
Costs
Treatment costs/month – €2440.15 €6181.33 €3679.04 – [31, 35, 36] –
T790M mutation testing €157.02 – – – – [37] –
Adverse events costs
Anemia €1945.59 €8.50 €20.92 €13.95 €122.69 – [38]
Leukopenia €1935.48 €8.45 – – €156.93 – –
Neutropenia €1399.53 €6.11 – €20.06 €252.17 – –
Diarrhea €1500.97 €216.30 €32.28 €16.14 – – [39]
Rash €87.99 €14.22 €0.95 €0.63 – – –
Dyspnea €827.16 – €2.96 €8.89 – – [40]
Stomatitis €1330.85 €116.23 €4.77 – €11.99 – –
Fatigue €83.63 €1.05 €0.58 €0.86 €10.14 – [41]
Paronychia €2.21 €0.25 €0.01 – – – [36]
Total cost per treatment for 
adverse events
– €371.11 €62.46 €60.54 €554.33 – –
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mutation test was taken into account for all patients pro-
gressing on first-line afatinib, as this is necessary to be eli-
gible for sequential treatment with osimertinib.
Model outputs
The budget impact analysis estimated the costs associated 
with each treatment approach. Costs were reported as annual 
total costs for the population and as quality-adjusted life 
months (QALMs).
In accordance with the ISPOR guidelines for budget 
impact analysis [21], the robustness of model assumptions 
and uncertainty around specific parameters were tested in 
one-way sensitivity analysis. These variables included the 
prevalence of the T790M mutation, subsequent treatment 
ratio’s after positive T790M mutation test, treatment cost for 
afatinib, osimertinib or PDC, respectively, and adverse event 
costs for different treatments. Model parameters mostly var-
ied by 20% with a maximum of 100% in the base-case value. 
Due to the high reported variance in detected T790M muta-
tions and recent data pointing towards heterogeneity between 
the first- and second-generation TKIs in tumor clonality and 
development of resistance mechanisms, sensitivity analyses 
were also performed to investigate how variance in detected 
T790M rates affected the model outcomes [29]. Results were 
displayed on tornado diagrams, ranked from the most sensi-
tive to least sensitive parameters.
Scenario analyses were performed to explore alternative 
assumptions in line with the suggestion of the ISPOR guide-
lines for budget impact analysis [21]. A scenario analysis 
was performed using the log-normal distribution for the fit-
ted patient survival data (compared to the Weibull distribu-
tion used in the base case) (Scenario A). A second scenario 
analysis was performed using a higher, real-world estimate 
(73.1%) of the proportion of patients treated with afatinib 
that developed a T790M mutation at progression on first-line 
treatment (Scenario B) [24]. Also, in line with the ISPOR 
guidelines for budget impact analysis, we did not elaborate 
confidence intervals for the scenarios in a formal statisti-
cal manner. Notably, scenarios are designed with a specific 
purpose to inform the decision maker without the idea to 
potentially compare them statistically. The rules of inference 
have limited relevance to the decisions which budget impact 
models seek to inform and decisions in this context are based 
on the mean net benefits in the scenarios [30].
Results
Outcomes survival analysis from the Weibull distribution 
in decision-analytic model for the various treatment para-
digms is shown in Fig. 2. An overview of the resulting mean 
time on treatment from each treatment strategy, percentage 
of patients receiving subsequent therapies, as well as esti-
mated QALM and total average costs per patient is shown in 
Table 1 in the Supplementary data. Overall, sequential treat-
ment with first-line afatinib had a mean total time on treat-
ment of 29.1 months, QALM of 20.2 with a mean cost of 
€108,166 per patient, in contrast to the treatment group with 
first-line osimertinib treatment that had a mean total time on 
treatment of 24.7 months, QALM of 17.4 for a mean cost 
per patient of €143,251. Treating with afatinib as first-line 
treatment would lead to an incremental time on treatment of 
4.5 months and incremental QALM of 2.8, together with a 
lower cost of €35,085 for total mean cost per patient versus 
first-line treatment with osimertinib.
AE adverse event, BSC best supportive care, PDC platinum doublet chemotherapy, PFS progression-free survival
Table 1  (continued)
Base case (range of sensitivity analysis)
Input data for one-way sensitivity analysis
Prevalence T790M (%) 63 (52.5–73.0)
Subsequent treatment T790M mutation positive (% patients) 88.0 (70.4–100.0)
Subsequent treatment after first-line osimertinib (% patients) 58.0 (46.4–80.0)
Afatinib cost (€) 2440.15 (1952.12–2928.18)
Osimertinib cost (€) 6181.33 (4945.07–7417.6)
PDC cost (€) 3679.04 (2943.23–4414.85)
T790M test cost (€) 157.02 (125.61–188.42)
Afatinib AE cost (€) 371.15 (296.89–445.33)
Osimertinib first-line AE cost (€) 62.46 (49.97–74.96)
Osimertinib second-line AE cost (€) 60.58 (48.46–72.65)
PDC AE cost (€) 554.33 (443.46–665.2)
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Budget impact analysis
Costs of each first-line treatment strategy were based on 
number of packages per year (a package is referred as one 
treatment cycle per patient; see appendix). The total budget 
impact of each treatment sequence is shown in Fig. 3. For 
the treatment sequence starting with afatinib, the total budget 
impact over 5 years was €110.4 million, with total costs per 
year ranging from €5.3 million in year 1 to €34.0 million for 
year 5. Introduction of osimertinib as second-line therapy in 
this strategy was responsible for 46% of the total cost in year 
3 and increased proportionally over time.
For the treatment sequence starting with osimertinib, the 
total budget impact over 5 years was €158.6 million, with total 
costs per year ranging from €11.34 million in year 1, increas-
ing to €36.98 million for the 3rd year, with lower incremental 
costs in years 4 and 5. The cost contribution of PDC to total 
costs was low reaching a maximum of 10% at year 5.
Fig. 2  Outcomes survival analysis with Weibull distribution in decision-analytic model: mean total time on treatment for patients by treatment 
paradigms. BSC best supportive care, PDC platinum doublet chemotherapy
Fig. 3  Total cost (€) per year 
for first-line treatment strategies 
afatinib versus osimertinib. 
PDC platinum doublet chemo-
therapy
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The incremental cost savings were €6.06, €12.25 million, 
€12.26 million, €9.87 million and €7.72 million for years 
1, 2, 3, 4 and 5, respectively (see Appendix). Over a 5-year 
period of time, the incremental budget impact savings of 
sequential treatment with afatinib versus first-line treatment 
with osimertinib were estimated to be €48.15 million.
Scenario analysis
Results of the two scenario analysis are presented in Table 2. 
Scenario A, with a log-normal distribution of the survival 
data showed a similar trend regarding budget impact out-
comes to the base-case analysis using the Weibull distribu-
tion. The incremental budget impact over a 5-year period 
yielded cost savings of €54.97 million when using sequential 
treatment with afatinib in comparison to first-line osimer-
tinib treatment. The second scenario analysis with 73.1% 
proportion of afatinib-treated patients receiving sequential 
treatment showed incremental budget impact cost savings 
of €41.34 million.
Sensitivity analyses
Figure 4 shows the effect of key parameters on the total 
annual cost impact over 5 years. The results were most sen-
sitive to the price of osimertinib and afatinib. Results were 
also sensitive to the percentage of patients with T790M 
mutation-positive disease receiving subsequent treatment, 
the percentage of patients testing positive for T790M muta-
tions and the percentage of subsequent treatment after first-
line therapy with osimertinib. The costs of adverse events 
for the different treatments and the cost of T790M mutation 
testing had only a minor influence on the incremental budget 
impact.
Discussion
Over the last decade, various treatment options showed 
improved PFS data in clinical trials and will support 
improvement of the burden of disease for lung cancer. The 
availability of these treatment options has an economic 
impact, therefore a budget impact analysis was performed 
to estimate the impact of first-line sequential treatment of 
afatinib versus the introduction of osimertinib as first-line 
therapy for NSCLC patients with common EGFR mutations 
in the Netherlands. The results of this analysis indicated that 
the incremental budget impact savings of first-line sequential 
treatment with afatinib in comparison to first-line sequential 
treatment with osimertinib was €48 million over a period of 
5 years. One-way sensitivity analysis showed the model was 
robust and the variables tested had no substantial influence 
on the incremental budget impact. As might be expected, 
the model was most sensitive to the price of osimertinib 
and afatinib. It is important to note that although there were 
differences in the tolerability of these agents, the increased 
frequency and costs of managing adverse events associated 
with afatinib were not associated with an increased over-
all treatment cost compared to osimertinib; afatinib had a 
lower total average cost per patient. Sensitivity analysis also 
showed that the costs associated with adverse events had lit-
tle influence on the incremental budget impact.
The results of the model were also sensitive to the per-
centage of patients with T790M mutation-positive disease 
receiving subsequent treatment, the percentage of patients 
testing positive for T790M mutations and the percentage of 
subsequent treatment after first-line therapy with osimerti-
nib. Indeed, the scenario analysis using a higher percent-
age for the proportion of patients that continued to receive 
second-line osimertinib following first-line afatinib resulted 
in smaller incremental budget impact savings due to a longer 
mean PFS time on second-line osimertinib and therefore 
increased drug costs. These results highlight the importance 
of T790M mutation testing, both for patient outcomes and 
assessment of treatment costs; further research is necessary 
to confirm the distribution and outcomes of T790M mutation 
testing. In addition, testing should already have been per-
formed at the first sign of progression on first-line therapy 
to prevent deterioration of the performance status related 
to progressive tumor growth. More data on the subsequent 
treatment options after first-line osimertinib, as alternatives 
to PDC, are also needed as there is no evidence to support 
other treatment approaches at this time.
To our knowledge, this is the first full budget impact 
analysis of first-line sequential therapy with afatinib in 
comparison to first-line osimertinib and was based on the 
best currently available evidence, a validated budget impact 
model, and included sensitivity and scenario analyses. No 
prior analysis has compared the budget impact of afatinib 
to osimertinib in newly diagnosed patients with metastatic 
NSCLC whose tumors have EGFR deletion 19 or L858R 
mutations. Recently, the Dutch Healthcare Institute evalu-
ated the budget impact of first-line osimertinib in NSCLC 
patients with EGFR mutations in the Netherlands over a 
3-year horizon showing an estimated incremental budget 
impact of €18.6 million to €37.1 million [31]. This is broadly 
in agreement with our findings. It should be noted that this 
analysis considered different treatment paradigms to ours; 
the first-line osimertinib treatment strategy included third-
line treatment with a PD-(L)1 inhibitor and the comparator 
arm included treatment with either a first- or second-gen-
eration TKI in the first-line setting and included a PD-(L)1 
inhibitor third line after PDC or PDC third line after osi-
mertinib second line. Our analysis did not include PD(L)1 
inhibitors, as this treatment approach is not recommended 
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Table 2  Overview of outcomes 
for base case and scenario 
analyses of budget impact 
analysis in sequential first-
line strategies afatinib versus 
osimertinib: number of claims, 
costs per year and budget 
impact
Year 1 Year 2 Year 3 Year 4 Year 5
Base case with Weibull distribution for the fitted patient survival data
Number of claims
First-line treatment strategy: start with afatinib
Afatinib 1656 3625 4491 4824 4941
Osimertinib 137 882 1851 2596 3030
PDC 69 338 576 728 815
First-line treatment strategy: start with osimertinib
Osimertinib 1796 4276 5495 5940 6071
PDC 56 400 794 1,020 1,108
Costs per year (€)
First-line treatment strategy: start with afatinib
Afatinib 4,149,352 8,954,515 11,066,631 11,880,180 12,165,881
Osimertinib 852,936 5,471,444 11,470,829 16,078,865 18,767,065
PDC 270,545 1,289,728 2,183,376 2,750,702 3,064,386
Total costs 5,272,832 15,715,687 24,720,828 30,709,746 33,997,331
First-line treatment strategy: start with osimertinib
Osimertinib 11,117,588 26,446,972 33,984,110 36,735,961 37,543,356
PDC 217,721 1,516,634 2,993,874 3,840,531 4,170,923
Total costs 11,335,309 27,963,606 36,977,985 40,576,492 41,714,309
Budget impact (€)
Afatinib 4,149,352 8,954,515 11,066,631 11,880,179 12,165,881
Osimertinib − 10,262,653 − 20,975,528 − 22,513,282 − 20,657,096 − 18,776,291
PDC − 52,824 − 226,906 − 810,507 − 1,089,829 − 1,106,567
Total budget impact − 6,062,477 − 12,247,919 − 12,257,157 − 9,866,746 − 7,716,987
Scenario A: log-normal distribution for the fitted patient survival data
Number of claims
First-line treatment strategy: start with afatinib
Afatinib 1652 3498 4369 4839 5120
Osimertinib 140 944 1886 2617 3134
PDC 70 367 612 766 862
First-line treatment strategy: start with osimertinib
Osimertinib 1802 4250 5622 6413 6899
PDC 54 410 774 997 1125
Costs per year (€)
First-line treatment strategy: start with afatinib
Afatinib 4,139,458 8,644,910 10,770,102 11,917,980 12,602,145
Osimertinib 876,051 5,857,182 11,687,707 16,211,293 19,405,814
PDC 276,751 1,395,414 2,314,444 2,888,088 3,233,655
Total costs 5,292,261 15,897,506 24,722,253 31,017,361 35,241,615
First-line treatment strategy: start with osimertinib
Osimertinib 11,160,108 26,291,129 34,767,384 39,659,294 42,662,810
PDC 208,204 1,553,835 2,915,326 3,746,964 4,221,615
Total costs 11,368,311 27,844,964 37,682,710 43,406,257 46,884,425
Budget impact (€)
Afatinib 4,139,458 8,644,910 10,770,102 11,917,980 12,602,145
Osimertinib − 10,284,056 − 20,433,947 − 23,079,677 − 23,448,011 − 23,256,996
PDC 68,548 − 158,421 − 600,881 − 858,876 − 987,960
Total budget impact − 607,651 − 11,947,458 − 12,910,457 − 12,388,897 − 11,642,810
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by ESMO or Dutch guidelines for patients with EGFR-acti-
vating mutations [2, 32].
Further cost-effectiveness analysis is necessary to con-
firm our cost and quality-of-life assessment comparison 
between first-line sequential treatment with afatinib versus 
first-line treatment with osimertinib. The cost-effectiveness 
of osimertinib has previously been evaluated in Canada [33], 
the United States and Brazil [34]. In the analysis conducted 
in Canada, first-line osimertinib therapy was compared to 
EGFR TKIs gefitinib and afatinib and was not considered 
as a cost-effective treatment option at a willingness-to-pay 
threshold of $100,000 per QALY [33]. Similar results were 
reported in the United States and Brazil using World Health 
Organization cost-effectiveness threshold criteria; at current 
costs osimertinib was unlikely to be cost-effective in either 
the United States or Brazil [34]. The clinical benefit of first-
line osimertinib over alternatives will likely carry the great-
est weight in funding decisions [33].
There are several limitations that should be considered. 
As no data were available on the efficacy and median PFS 
of PDC as third-line treatment, data from the second-line 
setting of the IMPRESS trial were used which likely over-
estimated the treatment benefit in this treatment arm and 
also overestimated the additional costs coming from this 
treatment benefit. To avoid an over- or underestimation on 
the quality of life of treatments resulting from the exclusion 
of adverse events for which disutility data were not avail-
able, assumptions were made for dyspnea, leukopenia, paro-
nychia and stomatitis. Further research regarding disutilities 
of adverse events is needed to support these assumptions. 
The intention of our model was to reconstruct the patients’ 
time on treatment per first-, second-, and third-line of treat-
ment based on the clinical trials for afatinib, osimertinib 
and PDC, respectively. As no direct head-to-head studies 
have compared afatinib versus osimertinib, this model used 
a mixed treatment model approach. One of the largest dif-
ferences between patient populations was the presence of 
the T790-positive mutation in all included EGFR-positive 
NSCLC patients in the AURA3 trial. The inclusion of these 
data had to be taken into account in our survival model to 
be able to reconstruct the effect of second-line treatment 
with osimertinib. The reason was that in the AURA3 trial 
the efficacy of second-line osimertinib was evaluated for this 
specific indication.
Even though the included RCTs were overall well bal-
anced, we are aware of potential selection bias due to 
PDC platinum doublet chemotherapy
Table 2  (continued) Year 1 Year 2 Year 3 Year 4 Year 5
Scenario B: alternative proportion of afatinib treated patients receiving sequential treatment (73.1%)
Number of claims
First-line treatment strategy: start with afatinib
Afatinib 1656 3625 4491 4824 4941
Osimertinib 159 1023 2148 3012 3516
PDC 51 258 464 615 711
First-line treatment strategy: start with osimertinib
Osimertinib 1796 4276 5495 5940 6071
PDC 56 400 794 1020 1108
Costs per year (€)
First-line treatment strategy: start with afatinib
Afatinib 4,149,352 8,954,515 11,066,631 11,880,180 12,165,881
Osimertinib 989,676 6,348,612 13,309,803 18,656,587 21,775,753
PDC 200,535 984,161 1,758,926 2,321,211 2,662,846
Total costs 5,339,563 16,287,288 26,135,360 32,857,978 36,604,479
First-line treatment strategy: start with osimertinib
Osimertinib 11,117,588 26,446,972 33,984,110 36,735,961 37,543,356
PDC 217,721 1,516,634 1,993,874 3,840,531 4,170,953
Total costs 11,335,309 27,963,606 36,977,985 40,576,492 41,714,309
Budget impact (€)
Afatinib 4,149,352 8,954,515 11,066,631 11,880,179 12,165,881
Osimertinib − 10,127,912 − 20,098,360 − 20,674,307 − 18,079,373 − 15,767,603
PDC − 17,186 − 532,473 − 1,234,948 − 1,519,320 − 1,508,107
Total incremental budget 
impact
− 5,995,746 − 11,676,318 − 10,842,624 − 7,718,514 − 5,109,829
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differences in patient populations such as age, race, smok-
ing history, EGFR mutations status and presence of T790M 
positive mutation, resulting in potential over- or underesti-
mation for both treatment arms.
The model did not include any other second- or third-
line treatment options than PDC therapy or second-line osi-
mertinib; it should be recognized that the inclusion of other 
emerging therapies would alter budget impact and total costs 
of both treatment strategies. Further research is needed with 
a head-to-head comparison of osimertinib versus afatinib 
and other second-generation TKIs in a clinical trial or real-
world data setting to support the outcomes of this budget 
impact model. Finally, compliance was assumed to be 100% 
for all treatments which may not reflect real-world practice. 
This may overestimate treatment costs and would also affect 
the clinical benefits of treatment.
In conclusion, the use of afatinib as a first-line treatment 
approach would have a substantial lower financial impact 
on the healthcare budget in the Netherlands and would lead 
to a higher incremental time on treatment of 4.5 months 
and an incremental QALM of 2.8 compared to a sequential 
treatment approach starting with osimertinib. The total 
budget impact over 5 years was €110.4 million for the 
sequence starting with afatinib versus €158.6 million for the 
sequence starting with osimertinib, leading to a total incre-
mental cost saving of €48.15 million. Together with clinical 
data, medicine prices and market access agreements will 
support governments and healthcare payers to decide how 
to manage the worldwide leading cause of cancer mortality.
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